Then, I got through that, made my way back to the mat, and had a huge performance that changed my career
Multi-Therapy Synergy Peptides work best when combined strategically: Peptides + Hormone Replacement: GH peptides synergize with optimized testosterone (men) or balanced estrogen/progesterone (women) Peptides + GLP-1: The combination discussed earlier for superior fat loss with muscle preservation Peptides + Metabolic Support: Metformin, berberine, or NAD+ therapy enhance peptide benefits Peptides + Lifestyle Coaching: Sleep optimization, stress management, and exercise programming multiply peptide effects The 1st Optimal Peptide Protocol Phase 1: Assessment (Weeks 1-2) Comprehensive intake and health history review Complete lab panel (hormones, metabolic markers, inflammatory markers) Goal setting and outcome metrics definition Education on peptide options and realistic expectations Phase 2: Optimization Foundation (Weeks 3-8) Address any underlying deficiencies (thyroid, nutrients, sleep, stress) Optimize base hormones if needed (testosterone, estrogen, progesterone) Establish lifestyle foundation (nutrition, exercise, recovery) Initiate first peptide based on primary goal and lab findings Phase 3: Peptide Titration (Weeks 9-20) Monitor response via symptoms, labs, and objective measures Adjust dosing to optimize outcomes and minimize side effects Add synergistic peptides if indicated (e.g., add tesamorelin to sermorelin for visceral fat) Fine-tune supporting interventions Phase 4: Maintenance and Evolution (Week 21+) Establish sustainable long-term protocol Quarterly lab monitoring and protocol adjustments Evolve strategy as goals and life circumstances change Ongoing education and optimization Experience the 1st Optimal Difference Work with a team that puts your safety first, uses only compliant peptides, and integrates peptide therapy into comprehensive functional medicine optimization
This article has been viewed 5,031,798 times
QD community oral or SC MOTS-c Daily SC, often 5 days on / 2 off AOD-9604 Daily SC Attribute Max studied dose SLU-PP-332 50 mg/kg BID (mouse, 28 days) MOTS-c 5-15 mg/kg (mouse) AOD-9604 1-5 mg/day in human Phase 2 Attribute Peak efficacy signal SLU-PP-332 ~25-30% fat-mass reduction in DIO mice over 28 days MOTS-c Improved insulin sensitivity in aged mice AOD-9604 Modest fat-loss signal in human Phase 2
MOTS-C promotes lipid utilization capacity by increasing oxygen consumption rate in muscle cells WITHOUT ramping up glycolytic flux
It's just less invasive, less daunting
